Title: Pharmacotherapy with oral Xa inhibitors for venous thromboembolism
Authors: Vanassche, Thomas ×
Vandenbriele, Christophe
Peerlinck, Kathelijne
Verhamme, Peter #
Issue Date: Apr-2015
Publisher: Ashley Publications
Series Title: Expert Opinion on Pharmacotherapy vol:16 issue:5 pages:645-58
Abstract: Introduction: Venous thromboembolism (VTE) causes substantial morbidity and mortality worldwide. The traditional treatment of VTE, with an initial therapy with (low molecular weight) heparin or fondaparinux and a continued treatment with vitamin K antagonists, is effective but has limitations. Areas covered: The current review summarizes the results of the Phase III trials with the new oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and provides a meta-analysis of these trials in the subgroups of elderly patients (> 75 years) and patients with impaired renal function. Expert opinion: The practical use of direct Xa inhibitors in the treatment of VTE in general and in specific subgroups is discussed. For elderly patients, patients with extremes of body weight, cancer patients or patients with moderate renal impairment, pooled data suggest that the direct oral Xa inhibitors are a reasonable alternative to standard therapy. For other indications, such as treatment of VTE in children, during pregnancy or in the context of heparin-induced thrombocytopenia, further data from clinical trials are needed.
ISSN: 1465-6566
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Molecular and Vascular Biology
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
expert opinion pharmacotherapy - vanassche.pdf Published 486KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science